Literature DB >> 30031681

STAT3 isoforms: Alternative fates in cancer?

Petra Aigner1, Valentin Just1, Dagmar Stoiber2.   

Abstract

Signal transducer and activator of transcription (STAT) 3 is the main mediator of IL-6-type cytokine signaling and an important transcriptional regulator of cell proliferation, maturation and survival. It has been described as a key player in cancer development and progression. However, under certain circumstances, STAT3 is also considered a potent tumor suppressor. This heterogeneity partially depends on its expression as different isoforms. Alternative splicing gives rise to two STAT3 isoforms, STAT3α and its truncated version STAT3β. Both isoforms are transcriptionally active and display distinct functions under physiological and pathological conditions. In fact, while STAT3α is widely described as an oncogene, STAT3β has gained attention as a potential tumor suppressor. This review provides a concise overview of the current knowledge on STAT3 during tumorigenesis, with special emphasis on the unique and complex roles of its alternatively spliced isoforms.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30031681     DOI: 10.1016/j.cyto.2018.07.014

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  18 in total

1.  Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain.

Authors:  Yaping Hua; Xing Yuan; Yun-Heng Shen; Jinxin Wang; Waqas Azeem; Shuo Yang; Alexandra Gade; Seyed Mohammad Lellahi; Anne Margrete Øyan; Xisong Ke; Wei-Dong Zhang; Karl-Henning Kalland
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

2.  Targeting the transcriptional activity of STAT3 by a novel fusion protein.

Authors:  Yanqiong Chen; Wenting Zhang; Xiufeng Bai; Yi Liu
Journal:  BMC Cancer       Date:  2022-07-10       Impact factor: 4.638

3.  Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents.

Authors:  Jimin Xu; Hyejin Kim; Jiabin Dong; Haiying Chen; Junhai Xu; Ruixia Ma; Mingxiang Zhou; Tianzhi Wang; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2022-03-10       Impact factor: 7.088

Review 4.  STAT3: Versatile Functions in Non-Small Cell Lung Cancer.

Authors:  Julian Mohrherr; Iris Z Uras; Herwig P Moll; Emilio Casanova
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

Review 5.  Nucleus, Mitochondrion, or Reticulum? STAT3 à La Carte.

Authors:  Lidia Avalle; Valeria Poli
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

6.  Expression of tSTAT3, pSTAT3727 , and pSTAT3 705 in the epithelial cells of hormone-naïve prostate cancer.

Authors:  Agnieszka Krzyzanowska; Nicholas Don-Doncow; Felicia Elena Marginean; Alexander Gaber; R William Watson; Rebecka Hellsten; Anders Bjartell
Journal:  Prostate       Date:  2019-03-24       Impact factor: 4.104

Review 7.  Transcriptional Regulation of Energy Metabolism in Cancer Cells.

Authors:  Sara Rodríguez-Enríquez; Álvaro Marín-Hernández; Juan Carlos Gallardo-Pérez; Silvia Cecilia Pacheco-Velázquez; Javier Alejandro Belmont-Díaz; Diana Xochiquetzal Robledo-Cadena; Jorge Luis Vargas-Navarro; Norma Angélica Corona de la Peña; Emma Saavedra; Rafael Moreno-Sánchez
Journal:  Cells       Date:  2019-10-09       Impact factor: 6.600

8.  Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.

Authors:  Zhong Hong; Zhaohong Wang; Bin Zhou; Jisheng Wang; Hongfei Tong; Yi Liao; Peng Zheng; Muhammad Babar Jamshed; Qiyu Zhang; Hui Chen
Journal:  Int J Oncol       Date:  2020-01-10       Impact factor: 5.650

9.  Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells.

Authors:  Julia Peñas-Martínez; Ginés Luengo-Gil; Salvador Espín; Nataliya Bohdan; Carmen Ortega-Sabater; Maria Carmen Ródenas; David Zaragoza-Huesca; María José López-Andreo; Carme Plasencia; Vicente Vicente; Alberto Carmona-Bayonas; Irene Martínez-Martínez
Journal:  Biomedicines       Date:  2021-05-07

Review 10.  STAT3 Activation and Oncogenesis in Lymphoma.

Authors:  Fen Zhu; Kevin Boyang Wang; Lixin Rui
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.